WO2001098267A8 - 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity - Google Patents

3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Info

Publication number
WO2001098267A8
WO2001098267A8 PCT/IB2001/001035 IB0101035W WO0198267A8 WO 2001098267 A8 WO2001098267 A8 WO 2001098267A8 IB 0101035 W IB0101035 W IB 0101035W WO 0198267 A8 WO0198267 A8 WO 0198267A8
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
opiate
pharmaceutically
opioid receptor
useful
Prior art date
Application number
PCT/IB2001/001035
Other languages
French (fr)
Other versions
WO2001098267A1 (en
Inventor
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Stephen Paul Gibson
Graham Lunn
Original Assignee
Pfizer Ltd
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Stephen Paul Gibson
Pfizer
Graham Lunn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002412188A priority Critical patent/CA2412188A1/en
Priority to PL01365956A priority patent/PL365956A1/en
Application filed by Pfizer Ltd, Bernard Joseph Banks, Douglas James Critcher, Ashley Edward Fenwick, David Morris Gethin, Stephen Paul Gibson, Pfizer, Graham Lunn filed Critical Pfizer Ltd
Priority to NZ523141A priority patent/NZ523141A/en
Priority to HU0301228A priority patent/HUP0301228A3/en
Priority to APAP/P/2002/002698A priority patent/AP2002002698A0/en
Priority to JP2002504223A priority patent/JP2004512263A/en
Priority to IL15342701A priority patent/IL153427A0/en
Priority to MXPA02012878A priority patent/MXPA02012878A/en
Priority to EA200201269A priority patent/EA005117B1/en
Priority to BR0111867-6A priority patent/BR0111867A/en
Priority to SK1717-2002A priority patent/SK17172002A3/en
Priority to AU62591/01A priority patent/AU781837B2/en
Priority to DZ013368A priority patent/DZ3368A1/en
Priority to EP01936728A priority patent/EP1292574A1/en
Priority to UY26787A priority patent/UY26787A1/en
Priority to UA20021210406A priority patent/UA73176C2/en
Publication of WO2001098267A1 publication Critical patent/WO2001098267A1/en
Priority to IS6637A priority patent/IS6637A/en
Priority to BG107329A priority patent/BG107329A/en
Priority to HR20020998A priority patent/HRP20020998A2/en
Priority to NO20026168A priority patent/NO20026168L/en
Publication of WO2001098267A8 publication Critical patent/WO2001098267A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I), where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma.
PCT/IB2001/001035 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity WO2001098267A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IL15342701A IL153427A0 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
BR0111867-6A BR0111867A (en) 2000-06-23 2001-06-07 3-Azabicyclo (3.1.0) hexane derivatives showing opioid receptor affinity
NZ523141A NZ523141A (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
HU0301228A HUP0301228A3 (en) 2000-06-23 2001-06-07 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them
APAP/P/2002/002698A AP2002002698A0 (en) 2000-06-23 2001-06-07 3-Azabicyclo[3.1.0] hexane derivatives useful in therapy.
JP2002504223A JP2004512263A (en) 2000-06-23 2001-06-07 3-Azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
PL01365956A PL365956A1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
MXPA02012878A MXPA02012878A (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity.
AU62591/01A AU781837B2 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
CA002412188A CA2412188A1 (en) 2000-06-23 2001-06-07 3-azabicyclo¬3.1.0|hexane derivatives useful in therapy
SK1717-2002A SK17172002A3 (en) 2000-06-23 2001-06-07 Derivatives of 3-azabicyclo[3,1,0]hexane as ligands of opiate receptors
EA200201269A EA005117B1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0)hexane derivatives having opioid 3-receptor affinity
DZ013368A DZ3368A1 (en) 2000-06-23 2001-06-07 3-AZABICYCLO DERIVATIVES [3.1.0] HEXANE HAVING AN AFFINITY FOR THE OPIOID RECEPTOR
EP01936728A EP1292574A1 (en) 2000-06-23 2001-06-07 3-azabicyclo[3.1.0]hexane derivatives having opioid receptor affinity
UY26787A UY26787A1 (en) 2000-06-23 2001-06-21 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY
UA20021210406A UA73176C2 (en) 2000-06-23 2001-07-06 3-azabicyclo(3.1.0)hexan derivatives having affinity to opioid receptor
IS6637A IS6637A (en) 2000-06-23 2002-11-28 3-azabicyclo [3.1.0] hexane derivatives useful in treatment
BG107329A BG107329A (en) 2000-06-23 2002-11-28 3-azabicyclo(3.1.0) hexane derivatives having opioid receptor affinity
HR20020998A HRP20020998A2 (en) 2000-06-23 2002-12-12 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity
NO20026168A NO20026168L (en) 2000-06-23 2002-12-20 Hexane derivatives having opioid receptor affinity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015562.2 2000-06-23
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles

Publications (2)

Publication Number Publication Date
WO2001098267A1 WO2001098267A1 (en) 2001-12-27
WO2001098267A8 true WO2001098267A8 (en) 2003-02-27

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001035 WO2001098267A1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Country Status (34)

Country Link
EP (1) EP1292574A1 (en)
JP (1) JP2004512263A (en)
KR (1) KR20040002386A (en)
CN (1) CN1639121A (en)
AP (1) AP2002002698A0 (en)
AR (1) AR028969A1 (en)
AU (1) AU781837B2 (en)
BG (1) BG107329A (en)
BR (1) BR0111867A (en)
CA (1) CA2412188A1 (en)
CZ (1) CZ20023967A3 (en)
DO (1) DOP2001000187A (en)
DZ (1) DZ3368A1 (en)
EA (1) EA005117B1 (en)
GB (1) GB0015562D0 (en)
HR (1) HRP20020998A2 (en)
HU (1) HUP0301228A3 (en)
IL (1) IL153427A0 (en)
IS (1) IS6637A (en)
MA (1) MA26915A1 (en)
MX (1) MXPA02012878A (en)
NO (1) NO20026168L (en)
NZ (1) NZ523141A (en)
OA (1) OA12293A (en)
PA (1) PA8519401A1 (en)
PE (1) PE20020253A1 (en)
PL (1) PL365956A1 (en)
SK (1) SK17172002A3 (en)
TN (1) TNSN01094A1 (en)
UA (1) UA73176C2 (en)
UY (1) UY26787A1 (en)
WO (1) WO2001098267A1 (en)
YU (1) YU91802A (en)
ZA (1) ZA200210278B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499557B2 (en) 2010-06-11 2016-11-22 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1440059E (en) * 2001-10-22 2008-05-16 Pfizer Prod Inc 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
ES2325782T3 (en) * 2002-05-17 2009-09-17 Tioga Pharmaceuticals, Inc. EMPLOYMENT OF EFFECTIVE COMPOUNDS AS SELECTIVE MODULATORS OF OPTICE RECEIVERS.
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
BRPI0507945A (en) * 2004-02-23 2007-07-24 Glaxo Group Ltd azabicyclic (3.1.0) hexane derivatives usable as dopamine d3 receptor modulators
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
ATE484502T1 (en) * 2005-06-14 2010-10-15 Glaxo Group Ltd NEW CONNECTIONS
EP2010518B1 (en) * 2006-04-03 2011-02-16 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
KR101208326B1 (en) 2007-03-30 2012-12-05 티오가 파마슈티칼스, 인코포레이티드 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
TWI423801B (en) * 2007-08-27 2014-01-21 Theravance Inc 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2015076310A1 (en) * 2013-11-20 2015-05-28 株式会社 三和化学研究所 Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
CA2985327A1 (en) 2015-05-20 2016-11-24 Sanwa Kagaku Kenkyusho Co., Ltd. Crystal of salt of 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof
BR112019016775A2 (en) 2017-02-17 2020-03-31 Trevena, Inc. DELTA-OPIOIDE MODULATING RECEIVER COMPOUNDS CONTAINING 7-MEMBER AZA-HETEROCYCLIC, METHODS OF USE AND PRODUCTION OF THE SAME
BR112019016827A2 (en) * 2017-02-17 2020-04-07 Trevena Inc 5-membered azaheterocyclic delta-opioid receptor modulating compounds, methods of use and production thereof
JPWO2018159716A1 (en) 2017-03-02 2019-12-26 株式会社三和化学研究所 Drugs for alcohol use disorders
CN108250088B (en) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 Preparation method of N, N, N '-trimethyl-N' -hydroxyethyl bisaminoethylether

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
AR245933A1 (en) * 1987-04-16 1994-03-30 Lilly Co Eli Piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (en) * 1993-12-04 1995-06-08 Basf Ag N-substituted 3-azabicycloalkane derivatives, their preparation and use
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499557B2 (en) 2010-06-11 2016-11-22 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
US9593124B2 (en) 2010-06-11 2017-03-14 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof

Also Published As

Publication number Publication date
UY26787A1 (en) 2002-01-31
PA8519401A1 (en) 2002-12-30
SK17172002A3 (en) 2004-09-08
EA200201269A1 (en) 2003-06-26
HUP0301228A2 (en) 2003-08-28
IL153427A0 (en) 2003-07-06
EP1292574A1 (en) 2003-03-19
IS6637A (en) 2002-11-28
BG107329A (en) 2003-07-31
MXPA02012878A (en) 2003-05-14
KR20040002386A (en) 2004-01-07
ZA200210278B (en) 2003-12-19
NO20026168D0 (en) 2002-12-20
BR0111867A (en) 2003-07-01
TNSN01094A1 (en) 2005-11-10
NO20026168L (en) 2003-02-18
PL365956A1 (en) 2005-01-24
CZ20023967A3 (en) 2004-02-18
HUP0301228A3 (en) 2005-08-29
UA73176C2 (en) 2005-06-15
AU6259101A (en) 2002-01-02
MA26915A1 (en) 2004-12-20
HRP20020998A2 (en) 2004-02-29
OA12293A (en) 2004-03-18
WO2001098267A1 (en) 2001-12-27
PE20020253A1 (en) 2002-04-08
AP2002002698A0 (en) 2002-12-31
AR028969A1 (en) 2003-05-28
CA2412188A1 (en) 2001-12-27
YU91802A (en) 2006-05-25
JP2004512263A (en) 2004-04-22
NZ523141A (en) 2005-06-24
CN1639121A (en) 2005-07-13
DOP2001000187A (en) 2002-03-30
GB0015562D0 (en) 2000-08-16
EA005117B1 (en) 2004-10-28
AU781837B2 (en) 2005-06-16
DZ3368A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
WO2001098267A8 (en) 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
WO2002036596A3 (en) CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2006116218A8 (en) Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
WO2003022813A1 (en) Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2007078523A3 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007149672A3 (en) Rebaudioside a composition and method for purifying rebaudioside a
WO2006034317A3 (en) Chemical compounds
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2009125923A3 (en) Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
MX2007005611A (en) Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
MA29623B1 (en) PYRAZOLO [3, 4-D] AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS
WO2003013435A3 (en) N-acetyl-d-glucosamine and process for producing n-acetyl-d-glucosamine
DE602004024188D1 (en) THE OPIOID RECEPTOR
WO2004014310A3 (en) Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
WO2004089908A3 (en) 3-azabicyclo[3.2.1]octane derivatives
WO2002080857A3 (en) Polymorphs of fexofenadine hydrochloride
WO2007127421A3 (en) Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
WO2005110409A3 (en) Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-918/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: DZP2002000315

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2001 107329

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2002-3967

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 17172002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 62591/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01768/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 153427

Country of ref document: IL

Ref document number: 523141

Country of ref document: NZ

Ref document number: P20020998A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2412188

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012878

Country of ref document: MX

Ref document number: 2001936728

Country of ref document: EP

Ref document number: 200210278

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 02115095

Country of ref document: CO

Ref document number: 200201269

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020027017503

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 20020857

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 018116086

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2002 504223

Country of ref document: JP

Kind code of ref document: A

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 2001936728

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027017503

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-3967

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 523141

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020027017503

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 62591/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 523141

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001936728

Country of ref document: EP